iSpecimen Inc. Files 8-K Report

Ticker: ISPC · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1558569

Sentiment: neutral

Topics: 8-K, filing, financials

TL;DR

iSpecimen filed an 8-K on Dec 13, 2024, covering other events and financial exhibits.

AI Summary

On December 13, 2024, iSpecimen Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. Specific details regarding the nature of these events or financial statements are not elaborated in the provided text.

Why It Matters

This 8-K filing signals that iSpecimen Inc. has made significant disclosures to the SEC, which could impact investors' understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate negative or positive financial implications detailed in the provided text.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for iSpecimen Inc.?

The filing is for "Other Events" and "Financial Statements and Exhibits," indicating disclosures related to the company's operations and financial status.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on December 13, 2024.

What is iSpecimen Inc.'s principal executive office address?

The principal executive offices are located at 8 Cabot Road, Suite 1800, Woburn, MA 01801.

What is the Commission File Number for iSpecimen Inc.?

The Commission File Number is 001-40501.

What is the IRS Employer Identification Number for iSpecimen Inc.?

The IRS Employer Identification Number is 27-0480143.

Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-13 16:01:24

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On December 13, 2024, iSpecimen Inc. (the "Company") announced positive results attributed to its Next Day Quote Program ("NDQ"), a next-day quote service for researchers and providers designed to accelerate the biospecimen transaction process. The NDQ program delivers accurate biospecimen sample pricing within 24 hours of receiving customer requests. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated December 13, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 13, 2024 iSPECIMEN INC. By: /s/ Robert Bradley Lim Name: Robert Bradley Lim Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing